NASDAQ:MCRB Seres Therapeutics (MCRB) Stock Forecast, Price & News $2.39 0.00 (0.00%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$2.29▼$2.4250-Day Range$2.33▼$5.0752-Week Range$2.28▼$9.49Volume2.69 million shsAverage Volume2.23 million shsMarket Capitalization$306.42 millionP/E RatioN/ADividend YieldN/APrice Target$13.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Seres Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside471.8% Upside$13.67 Price TargetShort InterestBearish15.91% of Shares Sold ShortDividend StrengthN/ASustainability-1.14Upright™ Environmental ScoreNews Sentiment0.98Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.14) to ($1.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.13 out of 5 starsMedical Sector490th out of 969 stocksPharmaceutical Preparations Industry226th out of 455 stocks 3.4 Analyst's Opinion Consensus RatingSeres Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.67, Seres Therapeutics has a forecasted upside of 471.8% from its current price of $2.39.Amount of Analyst CoverageSeres Therapeutics has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.91% of the outstanding shares of Seres Therapeutics have been sold short.Short Interest Ratio / Days to CoverSeres Therapeutics has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Seres Therapeutics has recently increased by 0.84%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSeres Therapeutics does not currently pay a dividend.Dividend GrowthSeres Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSeres Therapeutics has received a 71.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for infectious diseases", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Seres Therapeutics is -1.14. Previous Next 3.9 News and Social Media Coverage News SentimentSeres Therapeutics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Seres Therapeutics this week, compared to 2 articles on an average week.Search Interest28 people have searched for MCRB on MarketBeat in the last 30 days. This is an increase of 65% compared to the previous 30 days.MarketBeat Follows11 people have added Seres Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seres Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of Seres Therapeutics is held by insiders.Percentage Held by Institutions87.93% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Seres Therapeutics are expected to decrease in the coming year, from ($1.14) to ($1.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seres Therapeutics is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seres Therapeutics is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSeres Therapeutics has a P/B Ratio of 26.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Seres Therapeutics (NASDAQ:MCRB) StockSeres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is SER-109, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes SER-109 product candidate, which is developed for the treatment of CDI and recurrent CDI; collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease; research collaboration and option agreement with AstraZeneca Inc. for research and develop of microbiome in certain cancers and cancer immunotherapies, including research program for SER-401 targeting various cancers. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Read More MCRB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MCRB Stock News HeadlinesSeptember 24, 2023 | americanbankingnews.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 11, 2023 | msn.comSeres: VOWST Is A Great Product But Commercialization Prospects Unclear Due To Very High PriceSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 7, 2023 | finance.yahoo.comSeres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceSeptember 1, 2023 | msn.comSeres Therapeutics: Approved Drug And Nestle Partnership Make It A BuyAugust 9, 2023 | markets.businessinsider.comSeres Therapeutics (MCRB) Receives a Sell from Goldman SachsAugust 9, 2023 | finance.yahoo.comInvestors Don't See Light At End Of Seres Therapeutics, Inc.'s (NASDAQ:MCRB) TunnelAugust 8, 2023 | msn.comSeres Therapeutics' Q2 Revenues Top Estimates; Reports Encouraging VOWST Early Commercial UptakeSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsAugust 8, 2023 | finance.yahoo.comSeres Therapeutics (MCRB) Misses Q2 Earnings EstimatesAugust 8, 2023 | benzinga.comEarnings Outlook For Seres TherapeuticsAugust 8, 2023 | finance.yahoo.comSeres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdatesAugust 3, 2023 | msn.comSeres Therapeutics: VOWST's Time To ShineAugust 1, 2023 | finance.yahoo.comSeres Therapeutics to Present at Canaccord Genuity 43rd Annual Growth ConferenceAugust 1, 2023 | finance.yahoo.comSeres Therapeutics to Host Second Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on August 8, 2023July 25, 2023 | markets.businessinsider.com'Walk Away From It': Jim Cramer On This US Telecom Service ProviderJuly 10, 2023 | seekingalpha.comSeres Therapeutics: Microbiome Therapeutics Amid High Operational Costs And Uncertain Profitability PathJuly 7, 2023 | finance.yahoo.comSeres Therapeutics (NASDAQ:MCRB) shareholders have endured a 47% loss from investing in the stock five years agoJune 21, 2023 | finance.yahoo.comSeres Therapeutics Named to TIME100 Most Influential Companies ListJune 17, 2023 | finance.yahoo.comSeres Therapeutics and Nestlé Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023June 5, 2023 | msn.comSeres, Nestle Health announce US launch of c. diff therapy VowstJune 5, 2023 | finance.yahoo.comSeres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile InfectionJune 2, 2023 | finance.yahoo.comSeres Therapeutics to Present at Jefferies Healthcare ConferenceMay 30, 2023 | finance.yahoo.comSeres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST™May 23, 2023 | fool.comSeres Therapeutics (NASDAQ: MCRB)May 23, 2023 | seekingalpha.comSeres Q1 Earnings: Major News For InvestorsMay 22, 2023 | seekingalpha.comSeres Therapeutics: Still Work To Do Before Realizing Its PotentialSee More Headlines Receive MCRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MCRB Company Calendar Last Earnings8/08/2023Today9/28/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MCRB CUSIPN/A CIK1609809 Webwww.serestherapeutics.com Phone(617) 945-9626FaxN/AEmployees431Year FoundedN/APrice Target and Rating Average Stock Price Forecast$13.67 High Stock Price Forecast$25.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+484.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-250,160,000.00 Net Margins-3,509.50% Pretax Margin-117.68% Return on Equity-1,155.47% Return on Assets-45.89% Debt Debt-to-Equity Ratio4.45 Current Ratio3.23 Quick Ratio3.16 Sales & Book Value Annual Sales$7.13 million Price / Sales42.08 Cash FlowN/A Price / Cash FlowN/A Book Value$0.09 per share Price / Book26.00Miscellaneous Outstanding Shares128,210,000Free Float122,051,000Market Cap$300.01 million OptionableOptionable Beta2.63 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Eric D. Shaff M.B.A. (Age 47)Pres, CEO & Director Comp: $1.07MMr. David A. Arkowitz M.B.A. (Age 62)Exec. VP, CFO & Head of Bus. Devel. Comp: $670.02kDr. Matthew R. Henn Ph.D. (Age 48)Exec. VP & Chief Scientific Officer Comp: $643.83kMs. Paula A. Cloghessy SHRM-SCP (Age 51)SPHR, Exec. VP & Chief People Officer Comp: $521.27kDr. Lisa von Moltke M.D. (Age 64)Exec. VP & Chief Medical Officer Comp: $706.14kDr. David S. Ege Ph.D. (Age 48)Exec. VP & Chief Technology Officer Mr. Carlo Tanzi Ph.D.Investor Relations OfficerMr. Thomas J. DesRosier Esq. (Age 68)J.D., Chief Legal Officer, Exec. VP & Sec. Dr. Teresa L. Young Ph.D. (Age 56)R.Ph., Exec. VP and Chief Commercial & Strategy Officer Ms. Caroline HoldaAssistant Gen. CounselMore ExecutivesKey CompetitorsSilence TherapeuticsNASDAQ:SLNNanobiotixNASDAQ:NBTXPMV PharmaceuticalsNASDAQ:PMVPNuvation BioNYSE:NUVBMacroGenicsNASDAQ:MGNXView All CompetitorsInsiders & InstitutionsWolverine Trading LLCBought 11,300 shares on 8/23/2023Ownership: 0.000%Osaic Holdings Inc.Bought 188,139 shares on 8/21/2023Ownership: 0.148%California State Teachers Retirement SystemBought 7,351 shares on 8/21/2023Ownership: 0.094%Coppell Advisory Solutions LLCBought 8,342 shares on 8/17/2023Ownership: 0.007%Walleye Trading LLCSold 900 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions MCRB Stock - Frequently Asked Questions Should I buy or sell Seres Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MCRB shares. View MCRB analyst ratings or view top-rated stocks. What is Seres Therapeutics' stock price forecast for 2023? 5 analysts have issued 1 year price targets for Seres Therapeutics' shares. Their MCRB share price forecasts range from $7.00 to $25.00. On average, they predict the company's share price to reach $13.67 in the next twelve months. This suggests a possible upside of 484.0% from the stock's current price. View analysts price targets for MCRB or view top-rated stocks among Wall Street analysts. How have MCRB shares performed in 2023? Seres Therapeutics' stock was trading at $5.60 at the beginning of the year. Since then, MCRB stock has decreased by 58.2% and is now trading at $2.34. View the best growth stocks for 2023 here. When is Seres Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our MCRB earnings forecast. How were Seres Therapeutics' earnings last quarter? Seres Therapeutics, Inc. (NASDAQ:MCRB) released its quarterly earnings results on Tuesday, August, 8th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.55 by $0.19. The biotechnology company earned $126.50 million during the quarter, compared to analysts' expectations of $125.67 million. Seres Therapeutics had a negative net margin of 3,509.50% and a negative trailing twelve-month return on equity of 1,155.47%. Seres Therapeutics's revenue for the quarter was up 10441.7% on a year-over-year basis. During the same period last year, the firm earned ($0.70) earnings per share. What ETF holds Seres Therapeutics' stock ? Simplify Propel Opportunities ETF holds 550,626 shares of MCRB stock, representing 2.57% of its portfolio. What other stocks do shareholders of Seres Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD). When did Seres Therapeutics IPO? (MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers. What is Seres Therapeutics' stock symbol? Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB." Who are Seres Therapeutics' major shareholders? Seres Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include State Street Corp (6.68%), BlackRock Inc. (5.84%), Geode Capital Management LLC (1.53%), Jennison Associates LLC (1.09%), Point72 Asset Management L.P. (0.80%) and Handelsbanken Fonder AB (0.78%). Insiders that own company stock include David S Ege and Health Ltp Fund Ge Nutritional. View institutional ownership trends. How do I buy shares of Seres Therapeutics? Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Seres Therapeutics' stock price today? One share of MCRB stock can currently be purchased for approximately $2.34. How much money does Seres Therapeutics make? Seres Therapeutics (NASDAQ:MCRB) has a market capitalization of $300.01 million and generates $7.13 million in revenue each year. The biotechnology company earns $-250,160,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. How many employees does Seres Therapeutics have? The company employs 431 workers across the globe. How can I contact Seres Therapeutics? Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.serestherapeutics.com. The biotechnology company can be reached via phone at (617) 945-9626 or via email at ctanzi@serestherapeutics.com. This page (NASDAQ:MCRB) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.